Abstract:Yinfeng Wang, Xiaogen Tao, Peng Jin Department of Intensive Care Unit, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, People's Republic of China Correspondence: Xiaogen Tao; Peng Jin, Department of Intensive Care Unit, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, People's Republic of China, Email ; Background: This study examines the clinical outcomes and prognostic factors of COVID-19 in renal transplant recipients. Given their immunosuppressed status, these patients are at higher risk of severe complications from COVID-19. The study aims to provide healthcare professionals with critical insights for diagnosing and managing this vulnerable population. Patients and methods: This retrospective cohort study included adult renal transplant recipients diagnosed with COVID-19. Data on demographics, medical history, laboratory results, and patient outcomes were analyzed to identify clinical characteristics and prognostic factors. Results: This study included 115 renal transplant recipients with COVID-19, predominantly male, with a mortality rate of 10.4% (12 deaths). The overall vaccination rate was 20%. Univariate analysis showed significant differences between survivors and non-survivors in initial serum creatinine levels, and percentages of neutrophils, monocytes, and lymphocytes, along with CRP levels on day 3. Additionally, CRP levels, hemoglobin, and platelet counts on day 7 also differed significantly. Multivariate analysis identified CRP levels on days 3 and 7, day 7 hemoglobin and platelet counts, and concurrent bacterial infections as independent risk factors for mortality. Conclusion: Elevated CRP levels, renal impairment, and bacterial co-infections play a significant role in the outcomes of COVID-19 in kidney transplant recipients. This study highlights the importance of monitoring these factors for early identification and management of high-risk patients. Keywords: COVID-19, renal transplant recipients, clinical outcomes, prognostic factors, immunosuppression Since its emergence in late 2019, Coronavirus disease 2019 (COVID-19) has rapidly evolved into a global pandemic, affecting millions worldwide. As of February 2023, over 671.6 million cases and 6.8 million fatalities have been officially reported, underscoring the virus's devastating impact. 1 COVID-19 primarily manifests as a respiratory tract infection, with clinical presentations varying from mild, flu-like symptoms to severe acute respiratory distress syndrome (ARDS). 2 Extensive research identifies key risk factors for severe COVID-19 outcomes, including advanced age, obesity, diabetes mellitus, chronic pulmonary conditions, cardiovascular diseases, malignancies, and compromised immune systems. 3,4 Notably, immunosuppressed states, particularly those in solid organ transplant recipients, are associated with the highest risk of severe complications. 5,6 Intriguingly, some studies suggest that diminished inflammatory responses, attributed to weakened immune systems, may confer a degree of protection against severe manifestations of COVID-19. 7,8 Consequently, the clinical characteristics and prognoses of COVID-19 in immunocompromised individuals, especially those who have undergone solid organ transplants, warrant thorough investigation. Renal transplantation stands as the preferred treatment for individuals with end-stage renal disease, reflecting a global increase in such procedures. In 2021, the Global Observatory on Donation and Transplantation reported a significant milestone with over 92,500 renal transplants performed, a testament to the advancements in transplantation medicine and the advent of novel immunosuppressive medications. 9 Although these therapies are pivotal in mitigating organ rejection, they simultaneously heighten the susceptibility to viral, bacterial, and fungal infections among transplant recipients. 10 Moreover, the administration of immunosuppressive therapy has been independently associated with an adverse prognosis in a spectrum of infections. 11,12 Recent studies have underscored the importance of various prognostic markers in predicting COVID-19 outcomes among immunocompromised populations. Elevated levels of inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6), along with diminished lymphocyte counts, have been consistently associated with worse outcomes in these patients. 13,14 Consequently, we conducted a retrospective analysis of clinical manifestations, imaging data, laboratory results, and patient outcom -Abstract Truncated-

Clinical Characteristics and Immunosuppressant Management of Coronavirus Disease 2019 in Solid Organ Transplant Recipients

SARS-CoV-2 Infection in Transplant-Related Biology: Where Do We Stand?

LUNG TRANSPLANTATION DURING THE OUTBREAK OF CORONAVIRUS DISEASE 2019: EARLY EXPERIENCE FROM CHINA

Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center

Lung transplantation during the outbreak of Coronavirus Disease 2019 in China

Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort Study

Immunology of Transplant Patients with SARS-CoV-2 Infection: Transmission, Immune Response, and Therapeutic Strategy.

Different clinical presentations of two renal transplant recipients with coronavirus disease 2019: a case report

Prospective Clinical, Virologic, and Immunologic Assessment of COVID-19 in Transplant Recipients

Impact of solid organ transplant status on outcomes of hospitalized patients with COVID‐19 infection

Management of Immunosuppression in Kidney Transplant Recipients with COVID-19 Pneumonia: A Summary of 41 Confirmed Cases Reported Worldwide

Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19

Clinical Features and Prognostic Predictors in Patients with Renal Transplant Complicated by SARS-CoV-2 Infection, a Retrospective Single-Center Study

Withdrawing Mycophenolate Mofetil in Treating a Young Kidney Transplant Recipient with COVID-19

Clinical Characteristics of Novel Coronavirus Pneumonia in Organ Transplant Recipients and Management Strategy During the Epidemic(1st Edition)

Long-Term Clinical And Immunological Impact Of Severe Covid-19 On A Living Kidney Transplant Recipient - A Case Report

Ppa_a_337448 61..68

Effect of immunosuppression maintenance in solid organ transplant recipients with COVID-19: Systematic review and meta-analysis

The association between severe or death COVID-19 and solid organ transplantation: A systematic review and meta-analysis

Organ Transplantation Management in the Midst of the COVID-19 Outbreak: a Synopsis

A review of the clinical characteristics and management of immunosuppressed patients living with HIV or solid organ transplants infected with SARS-CoV-2 omicron variants